Depemokimab alone, without nasal steroid spray, for chronic rhinosinusitis with nasal polyps in Japan
Tests depemokimab alone in Japanese adults with chronic rhinosinusitis with nasal polyps.
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Japan9 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 28 people, planned
- Started
- 15 Jul 2026
- Expected to end
- 13 Jun 2028
- Type of study
- Interventional
- Treatments tested
- Depemokimab
- Record updated
- 8 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for Japanese adults with chronic sinus inflammation and nasal polyps (growths in the nose) not well controlled by standard treatment. They will get depemokimab without steroid nose sprays.
- Age
- 18 years and older.
- Sex
- Men and women can join.
- Disease stage
- Polyps in both sides of the nose, score of at least 5 out of 8 (at least 2 on each side). Severe symptoms: moderate or severe blocked nose, plus loss of smell or runny nose. Sinus symptoms for at least 12 weeks.
- Earlier treatment
- People must have had nose surgery to remove polyps, or at least three days in a row of steroid tablets or injections in the past 2 years for polyps, or be unable to take or tolerate such steroids. People cannot join if they used steroid nose sprays or washes for at least 8 weeks just before screening. No depemokimab, mepolizumab, reslizumab or benralizumab within 12 months, and no omalizumab, dupilumab or Tezpelumab within 130 days.
Main reasons for not taking part
- Cystic fibrosis, fungal sinus infection, a tumor in the nose, or antrochoanal polyps.
- Nose or sinus surgery within 6 months before the first visit.
- Conditions that raise eosinophils (a type of white blood cell), such as EGPA, or current vasculitis.
- Current cancer, or cancer in remission for less than 12 months.
- Pregnant or breastfeeding women, or women planning a pregnancy during the study.
The registry criteria, word for word
Show all 35 criteriaShow less
Who can take part
- 18 years of age and older inclusive, at the time of signing the informed consent
- Endoscopic bilateral NP score of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity) assessed by the investigator
- Participants who have had previous nasal surgery for the removal of nasal polyps, have used at least three consecutive days of systemic corticosteroids in the previous 2 years for the treatment of nasal polyps, or are medically unsuitable or intolerant to systemic corticosteroid
- Participants presenting with severe nasal polyp symptoms defined as symptoms of nasal congestion/blockade/obstruction with moderate or severe severity and loss of smell or rhinorrhoea (runny nose) based on clinical assessment by the investigator
- Presence of symptoms of chronic rhinosinusitis as described by at least 2 different symptoms for at least 12 weeks prior to Visit 1, one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip), or facial pain/pressure and/or reduction or loss of smell
- Male or eligible female participants
Who cannot take part
- Participants who had a sino-nasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of nasal polyp score
- Acute sinusitis or URTI at screening or in 2 weeks prior to screening
- Participants who have undergone any intranasal and/or sinus surgery (for example polypectomy, balloon dilatation or nasal stent insertion) within 6 months prior to Visit 1; nasal biopsy prior to Visit 1 for diagnostic purposes only is excepted
- Participants where NP surgery is contraindicated in the opinion of the Investigator
- Participants with a known, pre-existing parasitic infestation within 6 months prior to Visit 1
- Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis must be excluded prior to enrolment
- Participants that have been exposed to ionizing radiation in excess of 10 millisievert (mSv) above background over the previous 3-year period as a result of occupational exposure or previous participation in research studies
- Participants using INCS (including intranasal liquid steroid wash/douching) for at least 8 weeks immediately prior to screening
- Participants on inhaled corticosteroids exhalation through nose (Inhaled corticosteroids exhalation through nose [ICS/ETN]) method of administration for their asthma and NP for at least the 8 weeks immediately prior to screening
- Participants who have received depemokimab (Exdensur), mepolizumab (Nucala), reslizumab (Cinqair/Cinqaero), or benralizumab (Fasenra) within 12 months prior to Visit 1 or experienced treatment failure with monoclonal antibodies targeting IL-5/5R
- Participants who have received omalizumab (Xolair), dupilumab (Dupixent) or Tezpelumab (Tezpire) within 130 days prior to Visit 1
- Previously participated in any study with depemokimab, mepolizumab, reslizumab, or benralizumab and received study intervention (including placebo) within 12 months prior to Visit 1
- Nasal cavity tumor (malignant or benign)
- Participants with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndromes including (but not limited to) Eosinophilic granulomatosis with polyangiitis (EGPA) (formerly known as Churg-Strauss Syndrome) or Eosinophilic Esophagitis
- A known immunodeficiency (e.g., human immunodeficiency virus - HIV), other than that explained by the use of corticosteroids (CSs) taken as therapy for asthma
- A current malignancy or previous history of cancer in remission for less than 12 months prior to screening.NOTE: Participants that had localised carcinoma of the skin which was resected for cure will not be excluded
- Participants who have known, pre-existing, clinically significant cardiac, endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, hematological or any other system abnormalities that are uncontrolled with standard treatment
- Participants with allergy/intolerance to the excipients of depemokimab, a monoclonal antibody, or biologic
- Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice
- ALT >2* ULN
- Total bilirubin >1.5* ULN; For participants with Gilbert's syndrome can be included with total bilirubin >1.5* ULN if direct bilirubin is <=1.5* ULN
- As a result of medical interview, physical examination, or screening investigation the physician responsible considers the participant unfit for the study
- Cystic fibrosis
- Antrochoanal polyps
- Fungal rhinosinusitis
- Severe nasal septal deviation occluding one nostril preventing full assessment of nasal polyps in both nostrils
- Ongoing rhinitis medicamentosa (rebound or chemical induced rhinitis)
- Participants who have had an asthma exacerbation requiring admission to hospital within 4 weeks of screening
- Women who are pregnant or lactating or are planning on becoming pregnant during the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) without concomitant use of Intranasal corticosteroids (INCS) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
The group in the trial
- Depemokimab + SoCTreatment being tested
Participants will receive depemokimab along with their existing baseline maintenance CRSwNP standard of care (SOC) treatment (excluding INCS).
Treatment: Depemokimab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase IV, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of 100 mg SC Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Are Inadequately Controlled With Standard Treatment
- Plain-language title
- Depemokimab alone, without nasal steroid spray, for chronic rhinosinusitis with nasal polyps in JapanGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 8 September 2026